Mohamed Reda El Ochi, Mohamed Oukabli, Elarbi Bouaiti, Hafsa Chahdi, Adil Boudhas, Mohamed Allaoui, Ahmed Ameur, Mohamed Abbar, Abderrahmane Al Bouzidi
{"title":"人表皮生长因子受体2在膀胱尿路上皮癌中的表达。","authors":"Mohamed Reda El Ochi, Mohamed Oukabli, Elarbi Bouaiti, Hafsa Chahdi, Adil Boudhas, Mohamed Allaoui, Ahmed Ameur, Mohamed Abbar, Abderrahmane Al Bouzidi","doi":"10.1186/s12907-017-0046-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Urothelial bladder carcinoma (UBC) is one of the most prevalent cancers in men worldwide. Human epidermal growth factor receptor 2 (HER2) expression has been detected in a wide range of urothelial carcinoma. Despite many reports in the literature, the prognostic significance of this overexpression remains unclear. The aim of this study was to assess the expression of HER2 in urothelial bladder carcinomas and its association with clinical and pathological parameters.</p><p><strong>Methods: </strong>103 cases of UBC were diagnosed in our department between January 2014 and December 2015. The tumor specimens obtained by transurethral resection or cystectomy were evaluated by immunohistochemistry using HER2 antibody.</p><p><strong>Results: </strong>HER2 protein overexpression was present in 11.7% of cases and associated with tumor grade (<i>p</i> = 0.003) and pathological stage (<i>p</i> = 0.015). In multivariate analysis, HER2 overexpression was associated only with tumor grade (<i>P</i> = 0.04).</p><p><strong>Conclusion: </strong>HER2 protein overexpression is noted in patients with high grade cancer. This expression may select patients for anti HER2 targeted therapy. Future larger and prospective studies will verify the frequency of HER2 alteration and the role of HER2 in the aggressive behavior.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"17 ","pages":"3"},"PeriodicalIF":0.0000,"publicationDate":"2017-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-017-0046-z","citationCount":"14","resultStr":"{\"title\":\"Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma.\",\"authors\":\"Mohamed Reda El Ochi, Mohamed Oukabli, Elarbi Bouaiti, Hafsa Chahdi, Adil Boudhas, Mohamed Allaoui, Ahmed Ameur, Mohamed Abbar, Abderrahmane Al Bouzidi\",\"doi\":\"10.1186/s12907-017-0046-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Urothelial bladder carcinoma (UBC) is one of the most prevalent cancers in men worldwide. Human epidermal growth factor receptor 2 (HER2) expression has been detected in a wide range of urothelial carcinoma. Despite many reports in the literature, the prognostic significance of this overexpression remains unclear. The aim of this study was to assess the expression of HER2 in urothelial bladder carcinomas and its association with clinical and pathological parameters.</p><p><strong>Methods: </strong>103 cases of UBC were diagnosed in our department between January 2014 and December 2015. The tumor specimens obtained by transurethral resection or cystectomy were evaluated by immunohistochemistry using HER2 antibody.</p><p><strong>Results: </strong>HER2 protein overexpression was present in 11.7% of cases and associated with tumor grade (<i>p</i> = 0.003) and pathological stage (<i>p</i> = 0.015). In multivariate analysis, HER2 overexpression was associated only with tumor grade (<i>P</i> = 0.04).</p><p><strong>Conclusion: </strong>HER2 protein overexpression is noted in patients with high grade cancer. This expression may select patients for anti HER2 targeted therapy. Future larger and prospective studies will verify the frequency of HER2 alteration and the role of HER2 in the aggressive behavior.</p>\",\"PeriodicalId\":35804,\"journal\":{\"name\":\"BMC Clinical Pathology\",\"volume\":\"17 \",\"pages\":\"3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/s12907-017-0046-z\",\"citationCount\":\"14\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Clinical Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s12907-017-0046-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Clinical Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12907-017-0046-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma.
Background: Urothelial bladder carcinoma (UBC) is one of the most prevalent cancers in men worldwide. Human epidermal growth factor receptor 2 (HER2) expression has been detected in a wide range of urothelial carcinoma. Despite many reports in the literature, the prognostic significance of this overexpression remains unclear. The aim of this study was to assess the expression of HER2 in urothelial bladder carcinomas and its association with clinical and pathological parameters.
Methods: 103 cases of UBC were diagnosed in our department between January 2014 and December 2015. The tumor specimens obtained by transurethral resection or cystectomy were evaluated by immunohistochemistry using HER2 antibody.
Results: HER2 protein overexpression was present in 11.7% of cases and associated with tumor grade (p = 0.003) and pathological stage (p = 0.015). In multivariate analysis, HER2 overexpression was associated only with tumor grade (P = 0.04).
Conclusion: HER2 protein overexpression is noted in patients with high grade cancer. This expression may select patients for anti HER2 targeted therapy. Future larger and prospective studies will verify the frequency of HER2 alteration and the role of HER2 in the aggressive behavior.
期刊介绍:
BMC Clinical Pathology is an open access journal publishing original peer-reviewed research articles in all aspects of histopathology, haematology, clinical biochemistry, and medical microbiology (including virology, parasitology, and infection control). BMC Clinical Pathology (ISSN 1472-6890) is indexed/tracked/covered by PubMed, CAS, EMBASE, Scopus and Google Scholar.